Related Experiment Video

Updated: Jun 26, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Tyrosine kinase blockers: new hope for successful cancer therapy

Dariusz Pytel1, Tomasz Sliwinski, Tomasz Poplawski

  • 1Department of Molecular Genetics University of Lodz, Banacha 12/16 street, 90-237 Lodz, Poland.

Anti-Cancer Agents in Medicinal Chemistry
|January 20, 2009
PubMed

Insights

Tyrosine kinase (TK) blockers are revolutionizing cancer therapy by targeting abnormal signaling pathways. These targeted drugs show significant effectiveness across various cancers, including leukemia, breast, and prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinases (TKs) are crucial in cell signaling pathways regulating DNA repair, apoptosis, and proliferation.
  • Abnormal TK signaling is frequently implicated in tumor development and progression.
  • Targeting TKs offers a promising strategy for novel cancer therapies.

Purpose of the Study:

  • To review the chemistry, biological activity, and clinical potential of tyrosine kinase blockers for cancer treatment.
  • To highlight the impact of TK inhibitors in managing various human tumors.
  • To discuss emerging TK blockers in clinical development.

Main Methods:

  • Literature review of tyrosine kinase inhibitors.
  • Analysis of drug mechanisms of action and clinical efficacy.
  • Discussion of drugs in clinical development.

Main Results:

  • Tyrosine kinase blockers have demonstrated remarkable effectiveness in treating various cancers, including leukemias, head and neck, gastric, prostate, and breast cancers.
  • Imatinib (Gleevec) serves as a prime example, transforming chronic myelogenous leukemia treatment.
  • Several other TK inhibitors, such as Dasatinib, Gefitinib, Erlotinib, and Sunitinib, are actively used, with many more in clinical development.

Conclusions:

  • Tyrosine kinase blockers represent a significant advancement in targeted cancer therapy.
  • Continued research and development of TK inhibitors hold great promise for improving patient outcomes across a wide spectrum of malignancies.
  • The clinical potential of these targeted agents underscores their importance in modern oncology.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...